| abstract |
The present invention relates to an industrial process for synthesizing pharmaceutical compounds having the following structural formula (I) useful as tyrosine kinase inhibitors and more particularly as c-kit and bcr-abl inhibitors. R1 and R2 groups are the same or different and each represents a hydrogen, halogen atom, alkyl, alkoxy, trifluoromethyl, amino, alkylamino, dialkylamino, soluble group; m is 0-5 and n is 0-4; R 3 group represents an aryl or heteroaryl group, as described in the claims herein.n n n n n n n n ( I ) |